Anatomic Pathology Tests Diagnosing Chronic Ailments Rapidly
According to the United Nations Department of Economic and Social Affairs (UNDESA), the global population of people aged 65 years or above will increase from 727 million in 2020 to more than 1.5 billion by 2050. As age weakens the immune system, the elderly population is highly prone to chronic diseases such as cancer, cardiovascular diseases (CVDs), dementia, diabetes, organ failure, and chronic obstructive pulmonary disease (COPD), which can be diagnosed by using anatomic pathology. Thus, the surging population of the elderly will amplify the need for anatomic pathology tests in the foreseeable future.
Get Deep Analysis With Revenue Estimation: Anatomic Pathology Market
Additionally, the rising burden of chronic ailments, such as kidney diseases, cancer, autoimmune diseases, liver cirrhosis, hypertension, and heart diseases, especially in high and low- and middle-income countries (LMICs) will propel the anatomic pathology market at 5.8% CAGR during 2019–2024. According to P&S Intelligence, the market revenue will grow from $17.4 billion in 2018 to $24.3 billion by 2024. As per the World Health Organization (WHO), ischaemic heart disease, stroke, and COPD caused around 16%, 11%, and 6% of the total deaths all over the world, respectively, in 2019.
Consumables and instruments offered by Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffman–La Roche Ltd., Danaher Corporation, and Bio-Rad Laboratories Inc. are used in the fields of cardiology, nephrology, hepatology, and oncology for conducting surgical pathology, histopathology, and cytopathology tests. In the coming years, the popularity of histopathology tests will soar due to the surging number of tissue-related illnesses, such as infectious diseases and cancer, which can be diagnosed through this test. According to the WHO, cancer accounted for around 10 million deaths in 2020.
In the coming years, special staining-based anatomic pathology solutions will be adopted in the largest quantity due to the escalating number of genetic testing procedures across the world. Apart from these solutions, end-users are also using genetic testing, electron microscopy, and immunohistochemistry-based products in diseases diagnosis and drug discovery applications. Constant evolution in such technologies will result in the large-scale production of advanced and accurate anatomic pathology instruments and consumables in the forthcoming years.
Therefore, the rising cases of chronic illnesses and booming aging population will augment the need for anatomic pathology tests in the coming years.